EFFECTS OF NALOXONE ON THE SUBJECTIVE AND PSYCHOMOTOR EFFECTS OF NITROUS-OXIDE IN HUMANS

被引:17
作者
ZACNY, JP [1 ]
COALSON, DW [1 ]
LICHTOR, JL [1 ]
YAJNIK, S [1 ]
THAPAR, P [1 ]
机构
[1] UNIV CHICAGO,PRITZKER SCH MED,DEPT PSYCHIAT,CHICAGO,IL 60637
关键词
NITROUS OXIDE; NALOXONE; SUBJECTIVE; PSYCHOMOTOR; HUMAN; VOLUNTEER; ANTAGONIST; OPIATE; OPIOID;
D O I
10.1016/0091-3057(94)90071-X
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The effects of naloxone on the mood-altering and psychomotor-impairing effects of nitrous oxide were examined in two studies. Each of the double-blind, randomized trials tested effects of three doses of naloxone or saline placebo during inhalation of 30% nitrous oxide in oxygen or 100% oxygen placebo. Experiment 1 tested a range of naloxone doses used clinically to reverse opiate-induced respiratory depression (0, 0.01, 0.1, 1.0 mg/70 kg) and Experiment 2 included a dose approximately 25 times higher than that needed to reverse opiate-induced respiratory depression (0, 1.0, 3.0, 10 mg/70 kg). Nitrous oxide increased subject-rated reports of ''feel drug effect,''carefree,'' ''drunk,'' ''sedated,'' and ''high,'' and decreased psychomotor performance in both experiments. Naloxone had no effects by itself in either experiment, and, for the most part, did not significantly interact with nitrous oxide-induced changes in mood or psychomotor performance. Naloxone, in doses of 10 mg or less, does not appear to affect the subjective and psychomotor effects of nitrous oxide.
引用
收藏
页码:573 / 578
页数:6
相关论文
共 38 条
[1]   NITROUS-OXIDE ANALGESIA - RESEMBLANCE TO OPIATE ACTION [J].
BERKOWITZ, BA ;
NGAI, SH ;
FINCK, AD .
SCIENCE, 1976, 194 (4268) :967-968
[2]  
BERKOWITZ BA, 1977, J PHARMACOL EXP THER, V203, P539
[3]  
BICKEL WK, 1988, J PHARMACOL EXP THER, V244, P126
[4]  
BLUMBERG H, 1973, AGONIST ANTAGONIST A
[5]   NITROUS-OXIDE EFFECTS ON CEREBRAL EVOKED-POTENTIAL TO PAIN - PARTIAL REVERSAL WITH A NARCOTIC-ANTAGONIST [J].
CHAPMAN, CR ;
BENEDETTI, C .
ANESTHESIOLOGY, 1979, 51 (02) :135-138
[6]  
COHEN MR, 1981, LANCET, V2, P1110
[7]  
DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13
[8]  
DORRIS RL, 1992, FASEB J, V6, pA1282
[9]  
EMMANOUIL DE, 1991, 3RD IBRO WORLD C NEU, P211
[10]  
FRANK GB, 1975, ARCH INT PHARMACOD T, V217, P4